Fig. 5.

Neoantigen load is associated with benefit from ACT in melanoma. a Expressed predicted neoantigens are depicted in patients with and without clinical benefit from ACT. b, c The number of expressed predicted neoantigens by RECIST response b and clinical benefit status c. P-value from Kruskal–Wallis and Mann–Whitney tests, respectively. Solid black line indicates the median. d Expressed predicted neoantigen load is significantly associated with progression-free (PFS) and overall survival (OS). P-value from Cox regression. RECIST categories: CR complete response, PD progressive disease, PR partial response, SD stable disease